Cell line · CVCL_1232
Papers34
1 to 20 of 34
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PRMT5-mediated intron retention triggers innate and adaptive immunity against cancer. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Ribosomal modifications are associated with mesenchymal fate selection in the neural crest lineage. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the Sodium-Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| L-Glyceraldehyde Inhibits Neuroblastoma Cell Growth via a Multi-Modal Mechanism on Metabolism and Signaling. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1. | J Immunother Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Novel regulators of PrPC biosynthesis revealed by genome-wide RNA interference. | PLoS Pathog | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. | Cancer Discov | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| A Landscape of Pharmacogenomic Interactions in Cancer. | Cell | 2016 | Cellosaurus cites it | PubMed | |
| Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs. | Transl Oncol | 2013 | Cellosaurus cites it | PubMed | |
| PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. | Int J Cancer | 2012 | Cellosaurus cites it | PubMed | |
| NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. | Cell | 2010 | Cellosaurus cites it | PubMed | |
| Signatures of mutation and selection in the cancer genome. | Nature | 2010 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1232/papers